Core Insights - Cardinal Health delivered strong first-quarter results for fiscal 2026, exceeding both earnings and revenue expectations while raising full-year guidance [1][6] Financial Performance - Non-GAAP earnings per share (EPS) reached $2.55, surpassing the consensus estimate of $2.21 by 16% [2][9] - Revenue totaled $64.0 billion, exceeding estimates of $59.79 billion by 7% [2][9] - Non-GAAP operating earnings increased by 37% to $857 million, while GAAP operating earnings rose 18% to $668 million, indicating effective margin expansion [3][9] Segment Performance - The Pharmaceutical and Specialty Solutions segment, which constitutes 92% of total revenue, grew by 23% year over year to $59.2 billion, driving overall performance [2][5] - Global Medical Products saw modest growth of 2%, while the Other segment surged by 38%, highlighting successful diversification efforts [2] Guidance and Future Outlook - Full-year fiscal 2026 non-GAAP EPS guidance was raised to a range of $9.65 to $9.85, with a midpoint of $9.75 suggesting approximately $7.20 of EPS generation in the remaining three quarters [6] - Free cash flow guidance is set at $3.0 billion to $3.5 billion, indicating expectations for strong operational cash conversion into shareholder returns [6] - An accelerated share repurchase program of $375 million was initiated, reflecting management's confidence in the company's valuation [6] Strategic Moves - The acquisition of Solaris Health is anticipated to close in early November, expected to enhance specialty pharmaceutical services and contribute to earnings growth [7] Leadership Commentary - CEO Jason Hollar expressed satisfaction with the company's strong operational and financial performance, emphasizing consistent execution across all segments [10]

Core Insights - Cardinal Health, Inc. reported first-quarter fiscal 2026 adjusted earnings per share (EPS) of $2.55, exceeding the Zacks Consensus Estimate of $2.21 by 15.4%, and showing a year-over-year improvement of 35.6% [1][8] - Total revenue for the quarter reached $64 billion, marking a 22% increase year over year and surpassing the Zacks Consensus Estimate by 8.4% [2][8] Revenue Details - Sales increased by 22% year over year to $64 billion, beating estimates [2] Segmental Analysis - **Pharmaceutical and Specialty Solutions**: Revenues rose 23% to $59.2 billion, driven by growth in branded and specialty pharmaceutical sales [3] - **Pharmaceutical Profit**: Totaled $667 million, up 26% from the previous year, supported by brand and specialty products [4] - **Global Medical Products and Distribution**: Revenues reached $3.2 billion, a 2% increase year over year, with profits rising from $8 million to $46 million [4] - **Other Segment**: Sales grew 38% to $1.6 billion, with profits increasing 60% to $166 million, driven by strong performance across its operating segments [5] Margin Analysis - Gross profit increased 22% year over year to $2.32 billion, with a gross margin of 3.6% [6] - Distribution, selling, general and administrative expenses rose 14% to $1.46 billion [6] - Operating income was $668 million, an 18% increase year over year, with adjusted operating income up 37.1% to $857 million [6] Financial Update - The company ended the quarter with cash and cash equivalents of $4.59 billion, up from $3.87 billion in the previous quarter [9] - Net cash provided by operating activities was $973 million, compared to $1.65 billion used in the same period last year [9] 2026 Outlook - Cardinal Health raised its fiscal 2026 earnings guidance, expecting adjusted EPS between $9.65 and $9.85, up from a prior outlook of $9.30-$9.50 [10] - Projected revenue growth for the Pharmaceutical segment is 11-13%, with segment profit expected to increase 16-19% [10][11] - Medical segment revenues are estimated to grow 2-4%, while the Other segment is expected to see revenue growth of 26-28% [11] Conclusion - The company reported strong first-quarter results, with broad-based profit growth across all segments, particularly in Pharmaceutical and Specialty Solutions [12] - The positive results led to a 10% increase in shares during pre-market trading, with a year-to-date gain of 39.1% compared to the industry’s 4.1% [13]

Core Insights - Cardinal Health reported $60.16 billion in revenue for the quarter ended June 2025, a year-over-year increase of 0.5% and an EPS of $2.08 compared to $1.84 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $60.67 billion, resulting in a surprise of -0.84%, while the EPS exceeded the consensus estimate of $2.03 by +2.46% [1] Revenue Breakdown - Pharmaceutical and Specialty Solutions revenue was $55.37 billion, slightly below the average estimate of $55.86 billion, reflecting a year-over-year decline of -0.4% [4] - Corporate revenue reported at -$21 million, better than the estimated -$21.65 million, but a significant year-over-year decrease of -12.5% [4] - Other revenue reached $1.61 billion, surpassing the average estimate of $1.57 billion, marking a substantial year-over-year increase of +37.3% [4] - Medical Products and Distribution revenue was $3.2 billion, in line with the average estimate of $3.21 billion, showing a year-over-year growth of +2.9% [4] Segment Profit Analysis - Segment profit for Pharmaceutical and Specialty Solutions was $535 million, slightly below the average estimate of $543.86 million [4] - Segment profit for Other was $160 million, exceeding the average estimate of $147.91 million [4] - Global Medical Products and Distribution segment profit was $70 million, above the average estimate of $65.48 million [4] Stock Performance - Cardinal Health's shares have returned -2.5% over the past month, contrasting with the Zacks S&P 500 composite's +2% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Q3 FY25 Earnings Cardinal Health, Inc. May 1, 2025 © 2025 Cardinal Health. All Rights Reserved. 1 © 2025 Cardinal Health. All Rights Reserved. • Q3 FY25 Earnings Cautions Concerning Forward-Looking Statements Q3 Results © 2025 Cardinal Health. All Rights Reserved. 3 © 2025 Cardinal Health. All Rights Reserved. • Q3 FY25 Earnings This presentation contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These st ...

Group 1 - The upcoming report from Cardinal Health (CAH) is expected to show quarterly earnings of $2.15 per share, reflecting a 3.4% increase year-over-year [1] - Analysts forecast revenues of $55.03 billion for the quarter, indicating a 0.2% increase compared to the previous year [1] - The consensus EPS estimate has been revised 0.1% lower over the last 30 days, indicating a reevaluation of initial estimates by analysts [1][2] Group 2 - Analysts estimate that 'Revenue- Pharmaceutical and Specialty Solutions' will reach $50.33 billion, representing a -0.6% change from the year-ago quarter [4] - The 'Revenue- Medical Products and Distribution' is projected to be $3.21 billion, indicating a year-over-year increase of 3.2% [4] - Segment profit for 'Pharmaceutical and Specialty Solutions' is forecasted to be $635.77 million, up from $580 million in the same quarter last year [5] Group 3 - The 'Segment profit- Global Medical Products and Distribution' is expected to reach $44.16 million, compared to $20 million in the previous year [5] - Over the past month, Cardinal shares have recorded returns of +0.8%, while the Zacks S&P 500 composite has seen a -4.3% change [5] - Cardinal Health holds a Zacks Rank 3 (Hold), suggesting its performance will likely align with the overall market in the upcoming period [5]